[1] ZHOU M, WANG H, ZENG X, et al.Mortality, morbidity, and risk factors in China and its provinces, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet, 2019, 394(10204):1145-1158. [2] VILLANUEVA A.Hepatocellular Carcinoma[J]. N Engl J Med, 2019, 381(1):e2. [3] GOLABI P, FAZEL S, OTGONSUREN M, et al.Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities[J]. Medicine, 2017, 96(9):e5904. [4] OISHI K, ITAMOTO T, AMANO H, et al.Clinicopathologic features of poorly differentiated hepatocellular carcinoma[J]. J Surg Oncol, 2007, 95(4):311-316. [5] KUREBAYASHI Y, OJIMA H, TSUJIKAWA H, et al.Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification[J]. Hepatology, 2018, 68(3):1025-1041. [6] JONAS S, BECHSTEIN WO, STEINMULLER T, et al.Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis[J]. Hepatology, 2001, 33(5):1080-1086. [7] CHERNYAK V, FOWLER KJ, HEIKEN JP, et al.Use of gadoxetate disodium in patients with chronic liver disease and its implications for liver imaging reporting and data system (LI-RADS)[J]. J Magn Reson Imaging, 2019, 49(5):1236-1252. [8] LIN CL, KAO JH.Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants[J]. Best Pract Res Clin Gastroenterol, 2017, 31(3):249-255. [9] LEVRERO M, ZUCMAN-ROSSI J.Mechanisms of HBV-induced hepatocellular carcinoma[J]. J Hepatol, 2016, 64(1 Suppl):S84-S101. [10] MUSA J, LI J, GRUNEWALD TG.Hepatitis B virus large surface protein is priming for hepatocellular carcinoma development via induction of cytokinesis failure[J]. J Pathol, 2019, 247(1):6-8. [11] 乐晓华,刘琢冰,张香梅,等. 乙型肝炎患者肝细胞癌着丝粒蛋白K基因启动子区域甲基化水平的初步分析[J/CD]. 新发传染病电子杂志, 2021, 6(2):84-87. [12] LIM CJ, LEE YH, PAN L, et al.Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma[J]. Gut, 2019, 68(5):916-927. [13] 崔玉芝,时高峰,刘欢,等. 关于钆塞酸二钠及钆喷酸葡胺增强MRI对肝癌诊断效能的1∶1匹配的病例对照研究[J]. 临床放射学杂志, 2022, 41(1):81-85. [14] KUDO M. Will Gd-EOB-MRI change the diagnostic algorithm in hepatocellular carcinoma?[J]. Oncology, 2010, 78 Suppl 1:87-93. [15] KITAO A, MATSUI O, YONEDA N, et al.Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI[J]. AJR Am J Roentgenol, 2018, 211(2):347-357. [16] HAIMERL M, WACHTLER M, ZEMAN F, et al.Quantitative evaluation of enhancement patterns in focalR solid liver lesions with Gd-EOB-DTPA-enhanced MRI[J]. PLoS One, 2014, 9(6):e100315. [17] VOGL TJ, KUMMEL S, HAMMERSTINGL R, et al.Liver tumors: comparison of MR imaging with Gd-EOB-DTPA and Gd-DTPA[J]. Radiology, 1996, 200(1):59-67. [18] WELL L, WEINRICH JM, ADAM G, et al.Transient Severe Respiratory Motion Artifacts After Application of Gadoxetate Disodium: What We Currently Know[J]. Rofo, 2018, 190(1):20-30. [19] MOTOSUGI U, BANNAS P, BOOKWALTER CA, et al.An Investigation of Transient Severe Motion Related to Gadoxetic Acid-enhanced MR Imaging[J]. Radiology, 2016, 279(1):93-102. [20] ERRA P, PUGLIA M, RAGOZZINO A, et al.Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review[J]. Radiol Med, 2015, 120(11):1002-1011. [21] CHOI SY, KIM SH, PARK CK, et al.Imaging Features of Gadoxetic Acid-enhanced and Diffusion-weighted MR Imaging for Identifying Cytokeratin 19-positive Hepatocellular Carcinoma: A Retrospective Observational Study[J]. Radiology, 2018, 286(3):897-908. [22] EL-ASSAL ON, YAMANOI A, SODA Y, et al.Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver[J]. Hepatology, 1998, 27(6):1554-1562. [23] 刘丹,杨松青,张钧. 原发性肝癌超声造影诊断价值探讨[J]. 中华肿瘤防治杂志, 2014, 21(9):698-700. [24] DI MARTINO M, ANZIDEI M, ZACCAGNA F, et al.Qualitative analysis of small (≤2 cm) regenerative nodules, dysplastic nodules and well-differentiated HCCs with gadoxetic acid MRI[J]. BMC Medical Imaging, 2016, 16(1):62. [25] CHOI JW, LEE JM, KIM SJ, et al.Hepatocellular carcinoma: Imaging Patterns on Gadoxetic Acid-enhanced MR Images and Their Value as an Imaging Biomarker1[J]. Radiology, 2013, 267(3):776-786. [26] KITAO A, MATSUI O, YONEDA N, et al.Hypervascular hepatocellular carcinoma: Correlation between Biologic Features and Signal Intensity on Gadoxetic Acid - enhanced MR Images[J]. Radiology, 2012, 265(3):780-789. [27] YAMASHITA T, KITAO A, MATSUI O, et al.Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma[J]. Hepatology, 2014, 60(5):1674-1685. |